Biocon has turned ex-bonus from June 12, 2019 pursuant to the announcement in the board meeting held on April 25, 2019. The board has recommended the issue of bonus shares in proportion of one bonus share (face value of | 5 each) for every equity share held. Consequently, the share price has changed to | 263 /share. We remain positive on the stock on the back of strong prospects in both biologics and services (Syngene) segments. We believe the correction in the stock is overdone and the stock offers a compelling bet at the current level. We maintain our BUY...